Trial Profile
Compare the effect of extended-release toltoredine and solifenacin in the treatment of urinary frequency and nocturia in overactive bladder symptoms patients.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Dec 2017
Price :
$35
*
At a glance
- Drugs Solifenacin (Primary) ; Tolterodine (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- 21 Dec 2017 New trial record